Cellnovo Group(“Cellnovo” or the “Company” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, to day announces a capital raise of € 17.5 million, by means of a capital increase reserved to a category of persons through an accelerated book -building offering.